Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart


Date Filing Description Download
02/21/18 4 Statement of Changes in Beneficial Ownership
02/20/18 8-K Current report filing
02/15/18 8-K Current report filing
02/14/18 SC 13G/A Amended Statement of Ownership

Stock Quote

ACOR (Common Stock) $ 26.40 +0.00 (+0%) Volume: 518,680 MORE February 22, 2018

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *

Enter the code shown above.